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Abstract
Background: Fluoroquinolone resistance is a serious threat in the battle against the treatment of multi drug
resistant tuberculosis (MDR-TB) and extensively drug resistant tuberculosis (XDR-TB). Fluoroquinolone resistant
isolates from India had shown to have evolved several mutants in the quinolone resistance determining region
(QRDR) of DNA gyrase A subunit (GyrA), the target of fluoroquinolone. In view of high prevalence of mutations in
the ‘hot spot’ region, a study on combinatorial drug design was carried out to identify better analogues for the
treatment of MDR-TB. The gyrA subunit ‘hot spot’ region of codons 90, 94 and 95 were modeled into their
corresponding protein folds and used as receptors for the docking studies. Further, invitro tests were carried using
the parent compounds, namely gatifloxacin and moxifloxacin and correlated with the obtained docking scores.
Results: Molecular docking and in vitro studies correlated well in demonstrating the enhanced activity of
moxifloxacin, when compared to gatifloxacin, on ofloxacin sensitive and resistant strains comprising of clinical
isolates of MDR-TB. The evolved lead structures targeting against mutant QRDR receptors were guanosine and
cholesteryl esters of gatifloxacin and moxifloxacin. They showed consistently high binding affinity values of -10.3
and -10.1 kcal/mol respectively with the target receptors. Of these, the guanosine ester showed highest binding
affinity score and its log P value lied within the Lipinski’s range indicating that it could have better absorptivity
when it is orally administered thereby having an enhanced activity against MTB.
Conclusions: The docking results showed that the addition of the cholesteryl and guanosine esters to the ‘DNA
gyrase binding’ region of gatifloxacin and moxifloxacin enhanced the binding affinity of these parent molecules
with the mutant DNA gyrase receptors. Viewing the positive correlation for the docking and in vitro results with
the parent compounds, these lead structures could be further evaluated for their in vitro and in vivo activity against
MDR-TB.
Keywords: Docking, Mycobacterium tuberculosis, GyrA, Fluoroquinolones, gatifloxacin, moxifloxacin
Background
The resurgence of multi-drug resistant tuberculosis
(MDR-TB) [1] and HIV associated intractable mycobac-
terial infection are of serious global concern [2]. To con-
tain this situation, new anti-tuberculosis drugs and
reduced regimen treatments are of immediate require-
ment. Development of novel antituberculosis com-
pounds to combat MDR-TB is urgently needed.
Unfortunately, except for rifabutin and rifapentine there
are no new drugs available during the 40 years after the
release of rifampicin. The discovery of new drugs
involves several constraints that discourage many com-
panies from investing in novel anti-TB drugs. The
research is expensive, slow and difficult, and it requires
specialized facilities for handling Mycobacterium tuber-
culosis (MTB). Due to this situation, it is a matter of
urgency to develop other new anti-tuberculous drugs,
especially with the aid of bioinformatics-based drug
design, in order to tackle intractable TB [3]. The 8-
methoxy quinolones are highly efficacious in showing
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any medium, provided the original work is properly cited.potent anti-TB therapeutic activities in humans and ani-
mals, particularly when added to multidrug regimens,
[4,5] suggesting their usefulness as first-line drugs for
TB. They can also be used for the treatment of proven
MDR-TB, for the empirical treatment of TB in settings
of high rates of MDR-TB and for patients with severe
adverse reactions to ordinary first-line drugs [6]. These
fluoroquinolones bind to DNA gyrase thereby stabilizing
the covalent intermediate of DNA super coiling [7].
Currently they are used excessively in the treatment
against MDR-TB and XDR-TB [8]. Frequent usage of
these fluoroquinolones lead to resistance towards these
drugs. Missense mutations in the putative fluoroquino-
lone binding region of the A subunit has been found to
confer high level resistance and is referred to as QRDR.
The mutations in codons, 90 (Arg to val), 94 (Asp to
Asn, Gly) and 95 (Ser to Thr, Ala and Val), of gyrA
gene are found in the drug resistant strains of MTB [9].
But the new derivatives, moxifloxacin (MFX) and gati-
floxacin (GFX) are found to have more efficient activity
towards fluoroquinolone resistant MTB with a low
mean MIC. Hence, modern drug designing techniques
including quantitative structure activity relationship
(QSAR) [10], Molecular Docking etc. are widely used to
understand the structural features of compounds
responsible for pharmacological activities
In our study, the mutant GyrA molecules were mod-
eled as their crystal structures are not yet available and a
suitable antagonist design was carried out using molecu-
lar docking. The antagonist design was carried out with
the modifications involving hydrophilic and lipophilic
moieties. Hydrophilic moieties include Amino (NH2),
Hydroxyl (OH), Fluorine (F), phosphate, lactone, glucose
and esters of Adenine, Thymidine, Guanine and Cytidine.
While lipophilic moieties include benzene, napthalene,
phenanthacene, saturated lipid tails and cholestryl esters.
All these modifications were made at positions 3 and 7 in
the fluoroquinolone structure (Figure 1A) to identify ana-
logues which may exhibit better therapeutic efficacy
against MDR-TB [11]. These positions contribute to the
DNA gyrase binding and broad spectrum antibacterial
activity properties respectively. In addition, the theoreti-
cally calculated binding affinities of gatifloxacin and mox-
ifloxacin were compared with their MICs to have a
practical correlation for the docking studies.
Methods
Strain selection
The resistance pattern of 39 isolates of M. tuberculosis
isolated from chronically ill, sputum smear positive
patients with a history of previous anti tuberculosis
treatment received from various parts of India formed
the basis of this study. Of these 39 strains, 17 were sus-
ceptible to ofloxacin, which comprised of 11 MDR
strains (resistant at least to INH-isoniazid and RMP-
rifampicin), one strain resistant to INH alone, while the
remaining 5 susceptible to all drugs. Of the 22 ofloxacin
(OFX)-resistant strains, 21 were MDR strains and 1 was
resistant to INH alone. The drug susceptibility testing
for GFX and MFX was done by Absolute concentration
Figure 1 Common structural features of quinolones. (A) The modifications were made at positions 3 and 7, essential for binding to DNA-
gyrase complex and antibacterial spectrum respectively [20]. (B) and (C) are the chemical structures of gatifloxacin and moxifloxacin respectively.
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centrations as described Sulochana et al., [12] and the
results were used in this study.
Mutation identification of gyrA
Mutations present in the above strains (Figure 2) were
identified by sequencing PCR amplified product of gyrA
using automated sequencer ABI Prism model 377 ver-
sion 10.0 with Big dye terminator. The data obtained
were compared with the sequence available at the San-
g e rC e n t e ra n dN C B Iu s i n gB L A S Tp r o g r a m[ 1 3 ]a n d
the mutational pattern was compared with the phenoty-
pic susceptibility pattern [14].
Docking tools
The binding affinity of the analogues were obtained
using AUTODOCK Vina tool with AMBER force field
and Monte Carlo simulated annealing [15]. The dock-
ings were performed in a 64 bit PC. The receptor design
was made by using SWISS-MODEL, a fully automated
protein structure homology-modeling server. In this
tool, energy minimization and simulated annealing are
d o n ew i t ht h eG R O M O S 9 6f o r c e f i e l d[ 1 6 ] .T h e2D
structures of the ligands were drawn, optimized with
full hydrogen bonds and saved as. sk2 format using
ChemSketch tool from Advanced Chemistry Develop-
ment, Inc. [17] and the 3 D structures were obtained
using PRODRG server [18].
Receptors
Four “Hot spot” mutations (90 GTG, 94 AAC, 95 ATG
a n d9 5A C C )i nt h eQ R D Ro fG y r As u b u n i t( F i g u r e2 )
expressed in 7, 10, 11 and 107 in the clinical MTB iso-
lates respectively as described by Sulochana et al [14]
Figure 2 Mutations in the QRDR of gyrA gene of M. tuberculosis clinical isolates. The mutated codons and the corresponding amino acids
changes are shown at the bottom. The original sequence is shown in the box. Numbers indicate the number of isolates showing the mutations,
while the percentage denote the frequencies of occurrence of mutations at the particular codon [11].
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crystal structure (PDB: 3IFZ) elucidated by Piton et al.,
[19] was used for designing the mutant receptors. The
SWISS-MODEL receptor design was built from the 2.00
Å crystal structure coordinates of 25-kDa periplasmic
His/Glu/Gln/Arg/opine family-binding protein from Sili-
cibacter pomeroyi (PDB: 3L6V) since the available wild
type GyrA crystal structure (PDB: 3IFZ) based model
building was not successful for the mutated sequences
due to poor sequence alignment.
Ligands
The developed ligands using the ChemSketch tool were
based on the structures of GFX (Figure 1B) and MFX
(Figure 1C) since these drugs have better activity, both
in vitro [20,21] and in vivo against MDR-TB [22]. Var-
ious modifications in the ‘Antibacterial spectrum’ deter-
mining region and ‘DNA gyrase binding’ region of the
fluoroquinolone as mentioned by Emami et al.,[ 2 3 ] .
The ligands were designed using the structures of GFX
and MFX by using lipophilic and hydrophilic moieties at
positions 3 and 7, essential for binding to DNA-gyrase
complex and antibacterial spectrum respectively (Addi-
tional file 1, Figure S1).
Analysis of Binding
The binding sites for the docking were designed such
that the entire receptor molecule was included within
the selection grid. The highest binding energy values
corresponding to the RMSD value of zero were consid-
ered as the binding affinity value of the ligands for each
docking. The Hydrogen bond interactions were obtained
using Molegro molecular viewer [24] and Ramachandran
p l o t( F i g u r e3 )o b t a i n e df r o mD i s c o v e r ys t u d i o3 . 1
Visualizer [25] was used to confirm the integrity of the
designed protein fold.
Results
M I Cv a l u e sf o rM F X ,G F Xa n dO F Xo nv a r i o u ss t r a i n s
of Mycobacterium tuberculosis comprising of four
mutant codons in QRDR region of GyrA were given
(Table 1). The binding scores were calculated by using
AUTODOCK Vina tool and the binding affinity was
compared with their binding scores.
Figure 3 Structural view of receptors and their optimization. (A) PDB image of Mycobacterium tuberculosis D N Ag y r a s eA( P D B :3 I F Z ) .( B )
Modeled third mutant receptor corresponding to the QRDR of GyrA. (C) Ramachandran Plot for the third mutant receptor after energy
optimization.
Anand et al. BMC Structural Biology 2011, 11:47
http://www.biomedcentral.com/1472-6807/11/47
Page 4 of 13MIC of MFX vs Binding affinity scores
T h eM I Cv a l u eo fm o x i f l o x a c i nt ot h ef i r s tm u t a n t
receptor (codon 90 GTG) containing strain (Lab
No.944284) was 5 μg/ml and the binding affinity was
-7.9 kcal/mol. The same binding affinity value was also
observed for the second mutant receptor (codon 94
AAC) of OFX resistant strain. All the four ofloxacin
resistant strains with third mutant receptor (codon 94
ATG), showed MIC values between 2 to > 5 μg/ml for
MFX and a same binding affinity score of -7.9 kcal/mol.
The fourth mutant receptor (codon 95 ACC), consid-
ered as a natural polymorphism was found in 13 resis-
tant and 17 sensitive strains of ofloxacin. These 13
ofloxacin resistant strains which comprised of 12 MDR
and one INH mono resistant strain had the MIC for
moxifloxacin ranging from 1 to > 5 μg/ml with the
same binding affinity score of -7.9 kcal/mol. Of the 17
ofloxacin sensitive strains which comprised of 11 MDR,
5 Non MDR and 1 INH monoresistant strains, the MIC
for moxifloxacin was between 0.125 to 1 μg/ml with the
binding affinity score of -7.9 kcal/mol. Irrespective of
the sensitivity pattern for ofloxacin and MDR status, the
binding affinity values for moxifloxacin, remained the
same in all cases (Table 1).
MIC of GFX vs Binding affinity scores
Considering the first mutant receptor (codon 90 GTG)
containing strains, the MIC value of moxifloxacin to the
strain (Lab No.944284) was 5 μg/ml and the binding
affinity was -7.3 kcal/mol. The same binding affinity
value was also observed for the second mutant receptor
(codon 94 AAC) of ofloxacin resistant strain. With
respect to the third mutant receptor (codon 94 ATG),
all the four ofloxacin resistant strains showed the MIC
values between 2 to > 5 μg/ml for gatifloxacin with an
increased binding affinity score of -7.4 kcal/mol. The
fourth mutant receptor (codon 95 ACC), considered as
a natural polymorphism was found both in 17 sensitive
a n d1 3r e s i s t a n ts t r a i n so fo f l o x a c i n .O f1 3o f l o x a c i n
resistant strains which comprised of 12 MDR and one
INH mono resistant strain had the MIC for gatifloxacin
ranging from 2 to > 5 μg/ml. Of the 17 ofloxacin sensi-
tive strains which comprised of 11 MDR, 5 Non MDR
and 1 INH monoresistant strains, the MIC of gatifloxa-
cin ranging from 0.2 to 1 μg/ml. This mutant receptor
showed a binding affinity value of -7.3 kcal/mol (Table
1).
Interaction of MFX and GFX with the binding site
The interaction of MFX and GFX with the GyrA bind-
ing site showed that they interacted with different
amino acid residues at the active site (Figure 4). Only a
single H-bonding between the carboxyl oxygen and the
hydroxyl group of serine747 existed for moxifloxacin
whereas gatifoxacin showed two potential H-bond inter-
actions with asparagine 856 and tyrosine 564. But con-
sidering the high binding affinity value of moxifloxacin
(-7.9 kcal/mol) when compared to that of gatifloxacin
(-7.4 kcal/mol), as observed by Kitchen et al.,[ 2 6 ]i t
could be attributed to other bonding forces. The inter-
action of gatifloxacin with the second and third mutant
GyrA binding site showed thatw i t hb o t ht h er e c e p t o r s ,
the H-bond interactions occurs with the Tyrosine 564
and Asparagine 856. The H-bond energy between the
carboxyl group of gatifloxacin and the oxygen atom of
tyrosine yielded the -2.5 kcal/mol for the third mutant
receptor whereas it showed lower value of -1.411 kcal/
mol for the second mutant receptor in the presence of
non interacting phenylalanine 588. This may explain the
net lower affinity value of the second mutant receptor
(-7.3 kcal/mol) with respect to the third mutant receptor
(-7.4 kcal/mol) (Figure 5).
MIC vs Binding affinity correlation
The graphical representation of the binding affinity of
gatifloxacin and moxifloxacin with all the four different
mutants and wild type receptors showed relatively
greater binding affinity for moxifloxacin than gatifloxa-
cin (Figures 6A and 6B). When comparing to the MICs,
GFX and MFX showed better values for 7 and 8 out of
26 strains (for which the MIC values of both MFX and
GFX were determined) respectively (Table 1). Their
values remained equal for the remaining strains. Consid-
ering the graphical representation of MIC for MFX, it
can be seen that MFX is having a comparable bacterici-
dal activity to GFX with first, second and fourth mutant
receptors whereas it had enhanced activity with the
third mutant receptor. The binding energy shows a uni-
form improved activity for MFX when compared to
GFX. The large peak in the Figure 6B is because of the
poor activity of OFX (64 μg/ml) for the second mutant
when compared to GFX and MFX.
Docking analogues
In order to improve the binding affinity, two different
modifications on the ‘Antibacterial spectrum’ determin-
ing region and ‘DNA gyrase binding’ region, as
described by Emami et al., [20] were attempted in the
structures of GFX and MFX. The analogues are listed in
Additional file 1, Figure S1.
Modifications to ‘Antibacterial spectrum’ determining
region modifications
Increasing the aromaticity in this position showed a
marked increase in the binding affinity values ranging
from -7.9 (for Ligand 1) to -12.3 kcal/mol (for Ligand
19) with all the four mutants and wild type receptors.
Ligand 19 with seven aromatic and one cyclo hexane
Anand et al. BMC Structural Biology 2011, 11:47
http://www.biomedcentral.com/1472-6807/11/47
Page 5 of 13Table 1 MIC values of Moxifloxacin, gatifloxacin and ofloxacin on various strains of Mycobacterium tuberculosis
comprising the four mutant codons in QRDR region of gyrA.
Strain data S.
No.
Strain
No.
MDR status Resistance to
Ofloxacin
Area MFX
(μg/
ml)
GFX
(μg/
ml)
OFX
(μg/
ml)
First mutant - Codon 90 Ala-Val 1 944284 MDR R(M) Goa 5 5 8
2 940228 MDR R(L) Chennai NA NA 32
Binding affinity (kcal/mol) -7.9 -7.3 -7.4
Second mutant - Codon 94 Asp-
Asn
3 936837 MDR R(H) Sikkim NA NA 64
Binding affinity (kcal/mol) -7.9 -7.3 -7.4
Third mutant - Codon 94 Asp-Ala 4 912607 MDR R(H) Chennai NA NA 64
5 938424 MDR R(H) Karnataka 5 5 16
6 937532 MDR R(M) Chennai 2 5 8
7 939784 MDR R(M) Chennai > 5 2 32
8 940183 MDR R(L) Sikkim NA NA 16
9 RF0048 MDR R(H) NA 5 5 16
Binding affinity (kcal/mol) -7.9 -7.4 -7.1
Fourth mutant - Codon 95 Ser-Thr
(Natural polymorphism)
10 910659 MDR S Chennai 0.25 1 2
11 913168 MDR R(L) Chennai NA 8 16
12 916590 MDR R(M) Tamil
Nadu
NA 8 32
13 929925 MDR R(L) Chennai 1 1 8
14 932503 MDR S Chennai 0.5 0.5 2
15 933750 MDR R(H) NA 5 5 8
16 932504 MDR R(L) Chennai 2 2 8
17 937583 MDR R(L) Chennai 1 2 16
18 937911 MDR R(H) UP > 5 > 5 32
19 938066 Non MDR S Chennai NA NA 4
20 939184 MDR R(L) Chennai NA NA 8
21 939271 MDR S Chennai NA NA 4
22 940586 MDR R(H) AP 5 > 5 64
23 940742 Non MDR S Chennai 1 0.5 4
24 941935 INH resistant RMP
sensitive
R(L) Chennai NA NA 8
25 942100 MDR R(L) Chennai 5 5 16
26 947356 MDR R(M) Chennai 5 2 32
27 RF0071 MDR R(L) NA NA NA 8
28 939825 MDR S Chennai 1 1 4
29 939850 Non MDR S Chennai 0.25 0.5 2
30 940031 MDR S Chennai 0.25 0.5 4
31 940033 INH resistant RMP
Sensitive
S Chennai 0.5 0.5 2
32 RF0057 Non MDR S NA NA NA 2
33 RF0095 MDR S NA 0.5 0.2 2
34 RF0096 MDR S NA 0.125 0.2 2
35 RF0119 MDR S NA NA NA 2
36 RF0130 MDR S NA 0.25 0.2 2
37 RF0131 MDR S NA 0.25 0.5 2
38 949998 Non MDR S Chennai 1 0.5 4
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Page 6 of 13moieties attached in this position showed the highest
binding affinity, a value of -12.3 kcal/mol for all the four
mutant receptors (Table 2 and Figure 7). This indicated
that the mutations in the binding site did not affect the
binding affinity of this ligand. Binding site of the third
mutant receptor, with the ligand 19, showed three
hydrogen bond interactions with Glycine 640, Alanine
and Isoleucine 853 (Figure 7). The strongest interaction
was found between the Nitrogen atom at the 7
th posi-
tion of the piperazine ring and glycine, with a H-bond
energy of -2.5 kcal/mol and a bond length of 3.041 nm.
From the interactions it can be seen that the rigid aro-
matic side chain form a stacking effect in presenting the
interacting domain to the binding site. The net interac-
tions yielded a highest binding affinity (of -12.3 kcal/
mol) for this compound with this receptor (Table 2).
On the other hand, when this structure was modified so
as to replace the aromaticity with a saturated lipid tail
(Ligand 20), interestingly it showed a drastic decrease in
the binding affinity with all the four mutant receptors
namely -7.2, -6.1, -6.7 and -6.6 kcal/mol respectively,
which were the lowest binding affinity values when
compared to all other ligands (Table 2).
Modifications to ‘DNA gyrase binding’ region
The modifications to the ‘DNA gyrase binding’ region
mainly consisted of esters at the carboxyl site. The mod-
ifications at this site yielded docking scores ranging
from -7.7 (Ligand 38) to 10.4 (Ligand 35). With respect
to the nucleoside esters, Ligand 35, the guanosine ester
of moxifloxacin, showed the highest binding score
namely, -10.3 kcal/mol for first, second, third and wild
type receptors. Whereas for the fourth mutant receptor
it showed an enhanced score of -10.4. The increased
affinity of this ligand when compared to the other
nucleoside esters can be correlated to the four hydrogen
bond interactions it formed with Serine 747, valine 690,
Leucine 689 and arginine 658 (Figure 8). The strongest
interaction was found between the ester oxygen and
hydroxyl group of serine 747 with a H-bond energy of
Table 1 MIC values of Moxifloxacin, gatifloxacin and ofloxacin on various strains of Mycobacterium tuberculosis com-
prising the four mutant codons in QRDR region of gyrA. (Continued)
39 950629 MDR S Chennai 1 0.5 2
Binding affinity (kcal/mol) -7.9 -7.3 -7.6
Wild type (H37 Rv) 0.25 0.25 < 2
Binding affinity (kcal/mol) -7.9 -7.4 -7.6
Figure 4 Interactions of Moxifloxacin and Gatifloxacin with the third mutant receptor. The dotted light blue line shows the H-bond
interactions of Moxifloxacin (A) and Gatifloxacin (B). The H- bond interactions are indicated by arrow marking in the colour of the corresponding
amino acid.
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Page 7 of 13-2.5 kcal/mol and a bond length of 2.83 nm. The net
interactions yielded a binding affinity of -10.3 kcal/mol
for this compound with this receptor (Table 2).
Endogeneous ester modification of gatifloxacin, Ligand
36, which had a cholesteryl ester at this position, yielded a
reasonably good docking score (-10.1 kcal/mol) with
respect to first, third and wild type receptors (Table 2).
This good binding affinity arises from the H bond interac-
tion between the nitrogen atom in the 39
th position in the
structure and the carbonyl oxygen of Leucine 746. The
energy value of this interaction was -2.5 kcal/mol and a
bond length of 2.97 nm (Figure 9A). The docked image of
ligand 36 in the binding pocket of GyrA showed high
hydrophobic surface interactions which could also contri-
bute to the observed high binding affinity (Figure 9B).
From the results obtained, it could be concluded that
the binding affinity of moxifloxacin with that of the wild
type and all the four mutant receptors were similar with
au n i f o r ma f f i n i t yv a l u e( - 7 . 9k c a l / m o l ) .W h e r e a s ,f o r
gatifloxacin the binding affinity was -7.3 kcal/mol with
the first, second and fourth mutant receptors and a rela-
tively higher score of -7.4 kcal/mol with the third and
wild type receptors. The high binding affinity scores
obtained for moxifloxacin when compared to that for
GFX also correlates with their MIC values. Further,
ligand 36 and 35, with cholestryl and guanosine esters
respectively showed to be leading structures with good
binding affinity scores.
Discussion
Comparison between moxifloxacin and gatifloxacin for
resistant strains
Twenty nine strains of Mycobacterium tuberculosis
showed S-T polymorphism which did not code for any
resistance pattern but occurred as natural polymorphism
[27] were identified. Of these, 13 ofloxacin resistant
strains with no mutations showed phenotypic resistance
pattern which might be due to the efflux mechanisms
observed in M. smegmatis [28]. These resistant strains
showed high sensitivity to both moxifloxacin and gati-
floxacin (Figure 6). Our earlier in vitro findings on
actively growing and persister Mycobacterium tuberculo-
sis H37 Rv, showed that moxifloxacin is considered to
have good sterilizing activity in addition to early bacteri-
cidal activity [20]. This could be correlated with the
higher binding affinity calculated between the mutant
and wild type Gyr A receptors and moxifloxacin (-7.9
kcal/mol) when compared to the maximum binding affi-
nity output from gatifloxacin (-7.4 kcal/mol) (Table 1).
This could also be extended to the observation that
although gatifloxacin exhibited good bactericidal activity
against multiplying organisms it had very limited steri-
lizing activity against persisters [20].
Evaluation of lead structural analogues
The high docking score of cholestryl ester with all the
four mutant receptors can be due to the hydrophobicity
of the binding pocket of GyrA (Figure 9B). Guzman et
al., [29] showed that a cholesterol-rich diet accelerated
the sterilization rate of sputum cultures in pulmonary
tuberculosis patients, suggesting that cholesterol should
be used as a complementary measure in antituberculous
drug treatment. Study by Brzostek et al., [30] also
showed that cholesterol oxidase (ChoD), a well-known
cholesterol modification enzyme, is important for the
virulence for the tubercle bacillus. The theoretical pur-
pose of having a cholesterol moiety in the modified
fluoroquinolones in the form of esters is that it enables
Figure 5 Interactions of Gatifloxacin with the second and third mutant receptor. The dotted light blue line shows the H-bond interactions
of gatifloxacin with third (A) and second mutant receptors (B). The H- bond interactions are indicated by arrow marking in the colour of the
corresponding amino acid.
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is released in the presence of ChoD. However, the
mechanism of MTB uptake by mast cells is not known.
Munoz et al., [31] showed that Mycobacterium tubercu-
losis (MTB) enters into the mast cells through choles-
terol-enriched membrane microdomains (lipid rafts).
This supports our hypothesis that cholesterol conjugated
fluoroquinolones could have better penetrating effi-
ciency towards the intracellular MTB. This is also evi-
denced by a study carried out by Mohammed et al., [32]
who showed that the cholesterol content of the lipo-
some bilayer influenced the incorporation efficiency of
ibuprofen to the maximum. Schmalfuß et al.,[ 3 3 ]
showed that cholesterol increased the drug penetration
in the tissues. This is further supported with the
evidence showed by Simoes et al., [34], wherein lipophi-
lic ester prodrugs of Pyrazinamide (PZA) were found to
be active in concentrations 10-fold lower than those
needed for PZA.
In this study, the esters of nucleosides namely, ade-
nine, thymidine, guanine and cytosine were attempted
since the active site of the DNA gyrase has highly con-
served complementary residues for binding with the sin-
gle stranded DNA so as to prevent it from supercoiling.
This binding of DNA gyrase must be predominantly
involved in the interactions with the bases in the DNA
strand. This might support the enhanced binding affinity
of the modified drug containing nucleoside esters which
pairs with complementary bases in the single stranded
DNA. This nucleotide ester might also act by blocking
Figure 6 Comparison between binding energy and MIC. (A) Comparison of the docking scores with MIC of GFX, OFX and MFX for the wild
type. (B) Comparison of the docking scores with MIC of MFX, GFX and OFX for the mutants.
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Page 9 of 13Table 2 Docking scores of gatifloxacin, moxifloxacin and their new derivatives with respect the four mutant and the
wild type receptors
Ligand No. First mutant
Codon 90
Ala -Val
Second mutant
Codon 94
Asp-Asn
Third mutant
Codon 94
Asp-Ala
Fourth mutant
Codon 95
Ser-Thr
Wild type
Ciprofloxacin -7.5 -7.5 -7.4 -7.5 -7.5
Gatifloxacin -7.3 -7.3 -7.4 -7.3 -7.4
Lomefloxaciin -7.6 -7.6 -7.6 -7.6 -7.5
Moxifloxacin -7.9 -7.9 -7.9 -7.9 -7.9
Ofloxacin -7.6 -7.6 -7.6 -7.6 -7.6
Sparfloxacin -8.0 -8.0 -8.1 -8.1 -8.1
1 -8.0 -8.2 -8.2 -7.9 -8.2
2 -8.4 -8.5 -8.4 -8.4 -8.5
3 -8.1 -8.1 -8.5 -8.1 -8.1
4 -8.3 -8.1 -8.3 -8.4 -8.1
5 -8.2 -8.4 -8.4 -8.2 -8.5
6 -9.0 -9.0 -9.0 -9.0 -9.0
7 -9.2 -9.1 -9.2 -9.2 -9.1
8 -10.1 -10.0 -10.1 -10.1 -10.1
9 -9.5 -9.5 -9.5 -9.5 -9.5
10 -9.6 -9.7 -9.7 -9.7 -9.7
11 -9.5 -9.5 -10.0 -9.5 -9.5
12 -10.8 -10.8 -10.8 -10.7 -10.7
13 -10.2 -10.2 -10.2 -9.8 -10.2
14 -7.6 -7.5 -7.5 -7.5 -7.6
15 -7.9 -7.9 -7.9 -7.9 -7.9
16 -11.7 -11.7 -11.7 -11.7 -11.7
17 -11.4 -11.5 -11.5 -11.5 -11.5
18 -12.1 -12.1 -12.1 -12.1 -12.1
19 -12.3 -12.3 -12.3 -12.3 -12.0
20 -7.2 -6.1 -6.7 -6.6 -6.6
21 -8.4 -8.4 -8.4 -8.4 -8.4
22 -8.7 -8.7 -8.7 -8.7 -8.7
23 -8.9 -8.9 -8.9 -8.9 -8.9
24 -7.1 -7.1 -7.1 -7.1 -7.1
25 -8.6 -8.6 -8.6 -8.5 -8.6
26 -8.1 -8.7 -8.7 -8.7 -8.6
27 -9.0 -9.0 -9.2 -9.0 -9.1
28 -8.8 -9.7 -9.2 -9.7 -9.2
29 -8.8 -9.2 -9.2 -9.0 -9.0
30 -9.7 -9.0 -8.9 -9.0 -8.8
31 -8.9 -9.5 -9.3 -9.3 -9.5
32 -8.5 -8.7 -8.9 -9.0 -8.9
33 -9.4 -9.8 -9.4 -9.4 -9.4
34 -9.0 -9.0 -8.7 -9.0 -8.6
35 -10.3 -10.3 -10.3 -10.4 -10.3
36 -10.1 -10.0 -10.1 -9.8 -10.1
37 -9.0 -9.2 -9.2 -9.2 -9.2
38 -8.2 -8.0 -7.9 -7.7 -8.0
39 -8.6 -8.6 -8.6 -8.6 -8.6
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Page 10 of 13DNA replication. This type of mechanism is similar to
that approached for nucleoside analogues such as Riba-
virin, an antiviral agent. Its carboxamide group can
make the native nucleoside drug resemble like adenosine
or guanosine, depending upon its rotation. So, when
ribavirin is incorporated into RNA, as a base analog of
either adenine or guanine, it pairs equally well with
either uracil or cytosine, inducing mutations in RNA-
dependent replication in RNA viruses [35]. Earlier stu-
dies by Huang et al., showed that tyrosine 577, arginine
691 and arginine 745 are among the key DNA-binding
residues in M. tuberculosis DNA gyrase A subunit [36].
In this study, interestingly, GFX interacted with tyrosine
564, MFX interacted with serine 747, guanosine ester of
moxifloxacin (Ligand 35) formed H bond interactions
with Leucine 689, valine 690 and serine 747 moreover
cholestryl ester of gatifloxacin (Ligand 36) also showed
H bond interaction with leucine 746, all of which are
close to the key DNA-binding residues identified by
Huang et al.
In summary, the docking results showed that the addi-
tion of the cholesteryl and guanosine esters to the ‘DNA
gyrase binding’ region of gatifloxacin and moxifloxacin
enhanced the binding affinity of the parent molecule. M.
tuberculosis invades the macrophages via the cholesterol
dependent pathway [31] and this supports the hypoth-
esis that the lead cholestryl ester compound could have
a similar activity as that of pyrazinamide at acidic pH
Figure 7 Binding of Ligand 19 with the binding site of third mutant receptor. The H- bond interactions are indicated by arrow marking in
the colour of the corresponding aminoacid.
Figure 8 Binding of Ligand 35 with the binding site in the third mutant receptor. The H- bond interactions are indicated by arrow
marking in the colour of the corresponding amino acid.
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Page 11 of 13against intracellular MTB [37]. The guanosine ester
showed highest binding affinity score and its log P lies
between value of -0.45 and 2.69, which is within the
Lipinski’s range of 1 to 5 indicating that it could have
good absorptivity when it is orally administered thereby
having an enhanced activity against MTB.
Conclusion
The docking scores confirmed our earlier in vitro stu-
dies that moxifloxacin had a better killing activity than
gatifloxacin against Mycobacterium tuberculosis H37 Rv
[20,21]. The docking studies also yielded that increase in
the lipophilicity on either of the positions of the quino-
l o n es t r u c t u r ec o n s i d e r a b l yi n c r e a s e dt h eb i n d i n ga f f i -
nities. But owing to the toxicity of the benzene based
structures [38], cholesterol and guanosine conjugated
ligands of gatifloxacin and moxifloxacin are considered
to be a lead structures for further testing in the wet
laboratory.
Additional material
Additional file 1: Figure S1. Structures derived from Gatifloxacin and
Moxifloxacin by altering the functional groups of 7
th (A) and 3
rd (B)
positions of quinolone ring. The MFX or GFX moieties in the 7
th position
for 3
rd position modifications are indicated. M.W - Molecular weight.
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